There is a potential M&A market of almost $500 billion. With our assistance, you may reduce the time it takes to search a market and release your product.
What sets us apart is that our teams are heavily rooted in the process lifecycle, and we believe in providing comprehensive solutions to M&A businesses. Our customers benefit from the healthcare mergers and acquisitions consulting team’s expertise in data collection, strategy development, and the dissemination of peer deal alerts. Market projections, technological information, and therapeutic content are areas where our experts will assist you. The investment research team at SG Analytics (SGA) works closely with the life sciences and healthcare business insights team to provide you with the necessary due diligence.
Merger and acquisition (M&A) organizations and venture capitalists (VCs) in the pharmaceutical, life sciences, and devices industries always search for innovative technologies and prospective acquirers from developing and developed countries. So, we excel at spotting and analyzing new medical technologies, patent cliffs, patent disputes, new FDA and ANDA filings, peer competition, and more.
Why SGA
Industry Leaders
SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.
12+ Languages
Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.
White Papers
Emergence of Novel Immune - Mediated Therapies
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
White Papers
Future Trends and Technological Advances in Vaccine Treatment and Disease Prevention
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
White Papers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
CASE STUDIES
We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
